Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid Arthritis

INTRODUCTION: The biologics abatacept and adalimumab have different mechanisms of action (MoAs). We analyzed data from patients with rheumatoid arthritis treated in AMPLE (NCT00929864) to explore the pharmacodynamic effects of abatacept or adalimumab on anti-citrullinated protein antibodies (ACPAs)...

Descripción completa

Detalles Bibliográficos
Autores principales: Jabado, Omar, Maldonado, Michael A., Schiff, Michael, Weinblatt, Michael E., Fleischmann, Roy, Robinson, William H., He, Aiqing, Patel, Vishal, Greenfield, Alex, Saini, Jasmine, Galbraith, David, Connolly, Sean E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964842/
https://www.ncbi.nlm.nih.gov/pubmed/34878629
http://dx.doi.org/10.1007/s40744-021-00404-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964842/
https://www.ncbi.nlm.nih.gov/pubmed/34878629
http://dx.doi.org/10.1007/s40744-021-00404-x

Ejemplares similares